FDA accepts new drug application for Gilead's lymphoma drug Idelalisib

The US Food and Drug Administration (FDA) will review Gilead Sciences' new drug application (NDA) for idelalisib, an oral inhibitor of PI3K delta, to treat refractory indolent non-Hodgkin's lymphoma (iNHL).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news